Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Last updated: May 8, 2012
Sponsor: Pharmacology Research Institute
Overall Status: Completed

Phase

2

Condition

Depression

Affective Disorders

Depression (Major/severe)

Treatment

N/A

Clinical Study ID

NCT00290914
PRI #608
  • Ages 18-65
  • All Genders

Study Summary

The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female patients 18-65 years of age, inclusive.

Study Design

Study Start date:
Estimated Completion Date: